Kenvue Inc (KVUE)

Kenvue Inc. is a consumer health company whose common stock is listed on the New York Stock Exchange under the symbol KVUE. The company operates across the United States, the rest of North America, Europe, the Middle East, Africa, the Asia-Pacific region, and Latin America. Its business is organized into three segments: Self Care, Skin Health and Beauty, and Essential Health.

Kenvue’s product portfolio includes over-the-counter medicines for cough, cold and allergy relief, pain care, digestive health, smoking cessation, and eye care, along with naturally inspired self-care products, digital diagnostics, and telemedicine. It also markets face and body care, hair care, sun care, oral care, baby care, women’s health, wound care, tampons, cosmetics, vitamins, and supplements. The company sells products under a broad range of brands, including Benadryl, Tylenol, Zyrtec, Aveeno, Neutrogena, Listerine, BAND-AID, and Johnson’s. Incorporated in 2022, Kenvue is headquartered in Summit, New Jersey.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-KVUE
$22.20
17.0% Upside
Fair
$19.83
4.5% Upside
Fair
Fair
0.83
4.4%
August 12, 2026
22.5x
3.4x
2.4x
36.519 B
44.188 B
19.4%
99.9%
4.1
97.8%
112.4%
Valuation • Fair Value

Kenvue Inc (NYSE-KVUE) Fair Value by Valuation Model

Compare the primary fair value estimate for Kenvue Inc (NYSE-KVUE) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$22.20

Estimated upside of 17.0% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$22.64

Discounted cash flow valuation reference.

Ben Graham Formula Value

$9.37

Classic Ben Graham valuation formula reference.

DDM Fair Value

$32.34

Dividend discount model valuation reference.

EPV Fair Value

$17.28

Earnings power value estimate.

Comps Fair Value

$19.20

Comparable-company valuation reference.

Analyst Price Target

$19.83

Analysts imply upside of 4.5%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Kenvue Inc (NYSE-KVUE) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Kenvue Inc (NYSE-KVUE)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

15.292 B

Current operating scale indicator.

Revenue Forecast

15.629 B

Forward revenue estimate.

EBITDA

3.47 B

Current operating profitability reference.

EBITDA Forecast

3.748 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Kenvue Inc (NYSE-KVUE) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Kenvue Inc (NYSE-KVUE)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.48

No elevated caution signal from this screen.

Altman Z-Score

4.1

Relatively strong balance-sheet zone.

FCF / Net Income

112.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Kenvue Inc (NYSE-KVUE). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Kenvue Inc (NYSE-KVUE)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 12, 2026

Days to Earnings

22

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

4.4%

Income yield reference.

Upcoming Dividend

0.83

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

97.8%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Kenvue Inc (NYSE-KVUE), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Kenvue Inc (NYSE-KVUE) Stock Forecast & Technical Outlook

Review Kenvue Inc (NYSE-KVUE) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Kenvue Inc (NYSE-KVUE) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Kenvue Inc (NYSE-KVUE) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Kenvue Inc (NYSE-KVUE) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Kenvue Inc (NYSE-KVUE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Buy

The monthly technical read for Kenvue Inc (NYSE-KVUE) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Kenvue Inc (NYSE-KVUE)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Kenvue Inc (NYSE-KVUE) has a Hold consensus, with 1 buy, 12 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 12
Sell 0
FAQ Fast Investor Answers

Kenvue Inc (NYSE-KVUE) Stock FAQ

Quick answers about Kenvue Inc (NYSE-KVUE) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$22.20
Estimated upside 17.0%
Valuation Rating
Undervalued
Estimated upside of 17.0%
Analyst Target
$19.83
Implied upside 4.5%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Kenvue Inc (NYSE-KVUE) is $22.20. This implies an estimated upside of 17.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 17.0% versus the current market price.

The available analyst price target for Kenvue Inc (NYSE-KVUE) is $19.83. The analyst target implies estimated upside of 4.5%.

The current financial health read for Kenvue Inc (NYSE-KVUE) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Kenvue Inc (NYSE-KVUE) is August 12, 2026.

Based on the current data, dividend yield is 4.4%, upcoming dividend amount is 0.83.

The current P/E ratio listed for Kenvue Inc (NYSE-KVUE) is 22.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Kenvue Inc is 36.519 B.

The current enterprise value listed for Kenvue Inc is 44.188 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Kenvue Inc is NYSE-KVUE, and the stock is listed on NYSE.

Kenvue Inc (NYSE-KVUE) is listed on NYSE.

The current debt-to-total-capital ratio listed for Kenvue Inc is 19.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Kenvue Inc is 99.9%. Free float helps investors understand how much of the share base is available for public trading.